

## PRODUCT MONOGRAPH

### **M-M-R<sup>®</sup> II**

(measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.)

Single-dose vials

Lyophilized powder for injection

(0.5 mL/dose after reconstitution)

Active Immunizing Agent  
Against  
Measles, Mumps and Rubella (German measles)

**Merck Canada Inc.**  
16750 route Transcanadienne  
Kirkland, QC Canada H9H 4M7  
www.merck.ca

**Submission Control No:** 200811

**Date of Approval:** February 17, 2017

## Table of Contents

<b>PART I: HEALTH PROFESSIONAL INFORMATION.....</b>	<b>3</b>
SUMMARY PRODUCT INFORMATION .....	3
DESCRIPTION.....	3
INDICATIONS AND CLINICAL USE.....	4
CONTRAINDICATIONS .....	4
WARNINGS AND PRECAUTIONS.....	6
ADVERSE REACTIONS.....	8
DRUG INTERACTIONS .....	13
DOSAGE AND ADMINISTRATION .....	13
OVERDOSAGE .....	16
ACTION AND CLINICAL PHARMACOLOGY .....	17
STORAGE AND STABILITY.....	17
DOSAGE FORMS, COMPOSITION AND PACKAGING .....	18
<b>PART II: SCIENTIFIC INFORMATION .....</b>	<b>20</b>
PHARMACEUTICAL INFORMATION.....	20
CLINICAL TRIALS .....	20
REFERENCES .....	24
<b>PART III: CONSUMER INFORMATION.....</b>	<b>27</b>

## M-M-R<sup>®</sup> II

(measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.)

### PART I: HEALTH PROFESSIONAL INFORMATION

#### SUMMARY PRODUCT INFORMATION

Route of Administration	Dosage Form / Strength	Clinically Relevant Nonmedicinal Ingredients
Subcutaneous	Lyophilized powder for injection  0.5 mL dose after reconstitution  Measles: $\geq 1000$ CCID <sub>50</sub> Mumps: $\geq 5000$ CCID <sub>50</sub> Rubella: $\geq 1000$ CCID <sub>50</sub>	Gelatin, neomycin, recombinant human albumin  <i>For a complete listing see DOSAGE FORMS, COMPOSITION AND PACKAGING section.</i>

#### DESCRIPTION

M-M-R<sup>®</sup> II (measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.) is a sterile lyophilized preparation of (1) ATTENUVAX<sup>®</sup> (measles virus vaccine, live, attenuated, Merck Frosst Std.), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX<sup>®</sup> (mumps virus vaccine, live, attenuated, Merck Frosst Std.), the Jeryl Lynn<sup>®</sup> (B level) strain of mumps virus propagated in chick embryo cell cultures; and (3) MERUVAX<sup>®</sup> II (rubella virus vaccine, live, attenuated, Merck Frosst Std.), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in human diploid lung fibroblasts (see WARNINGS AND PRECAUTIONS, Immune and Hypersensitivity).<sup>1,2</sup>

The growth medium for measles and mumps is Medium 199 (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing SPGA (sucrose, phosphate, glutamate, and recombinant human albumin) as stabilizer and neomycin.

The growth medium for rubella is Minimum Essential Medium (MEM) (a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum) containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests.

The cells, virus pools and fetal bovine serum are all screened for the absence of adventitious agents.

## INDICATIONS AND CLINICAL USE

M-M-R<sup>®</sup> II is indicated for simultaneous vaccination against measles, mumps, and rubella in persons 12 months of age or older.<sup>3</sup> A second dose of M-M-R<sup>®</sup> II is recommended (see DOSAGE AND ADMINISTRATION, Revaccination).<sup>3</sup>

Infants who are less than 12 months of age may fail to respond to the measles component of the vaccine due to presence in the circulation of residual measles antibody of maternal origin; the younger the infant, the lower the likelihood of seroconversion. In geographically isolated or other relatively inaccessible populations for whom immunization programs are logistically difficult, and in population groups in which wild-type measles infection may occur in a significant proportion of infants before one year of age, it may be desirable to give the vaccine to infants during their first year of life. Infants vaccinated under these conditions at less than 12 months of age should be revaccinated (two additional doses) after reaching 12 months of age.<sup>3</sup> There is some evidence to suggest that infants who are born to mothers who had wild-type measles and who are vaccinated at less than one year of age may not develop sustained antibody levels when later revaccinated. The advantage of early protection must be weighed against the chance for failure to respond adequately on reimmunization.<sup>4</sup>

Previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women should receive live attenuated rubella vaccine (such as that contained in monovalent vaccine or in M-M-R<sup>®</sup> II) to reduce the risk of exposure of the pregnant woman.

Individuals planning travel abroad, if not immune, can acquire measles, mumps, or rubella and import these diseases to their country. Therefore, prior to international travel, individuals known to be susceptible to one or more of these diseases can receive either a monovalent vaccine (measles, mumps or rubella), or a combination vaccine as appropriate. However, M-M-R<sup>®</sup> II is preferred for persons likely to be susceptible to mumps and rubella; and if monovalent measles vaccine is not readily available, travelers should receive M-M-R<sup>®</sup> II regardless of their immune status to mumps or rubella.<sup>5-7</sup>

Vaccination has been recommended for susceptible individuals in high-risk groups such as students at post-secondary institutions, health care workers and military personnel.<sup>3</sup>

Passively acquired antibody can interfere with the response to live, attenuated-virus vaccines. Therefore, administration of M-M-R<sup>®</sup> II should be deferred until approximately three months after passive immunization.<sup>8</sup>

## CONTRAINDICATIONS

Hypersensitivity to any component of the vaccine including gelatin. *For a complete listing, see DOSAGE FORMS, COMPOSITION AND PACKAGING section.*

Do not give M-M-R<sup>®</sup> II to pregnant females; the possible effects of the vaccine on fetal development are unknown at this time. If vaccination of post-pubertal females is undertaken, pregnancy must be avoided by medically acceptable methods for three months following vaccination (see WARNINGS AND PRECAUTIONS, Pregnant Women).

Histologic changes, similar to those seen in gestational rubella, have been observed and rubella virus has been recovered from decidua following vaccination of pregnant women with live attenuated rubella vaccine. These vaccines may thus constitute a risk to the fetus.

Anaphylactic or anaphylactoid reactions to neomycin. Each dose of reconstituted vaccine contains approximately 25 µg neomycin.

Any febrile respiratory illness or other active febrile infection.

Active untreated tuberculosis.

Patients receiving immunosuppressive therapy with ACTH, corticosteroids, irradiation, alkylating agents or antimetabolites. This contraindication does not apply to patients who are receiving corticosteroids as replacement therapy, e.g., for Addison's disease.

Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.

Primary and acquired immunodeficiency states, including patients who are immunosuppressed in association with AIDS or other clinical manifestation of infection with human immunodeficiency viruses; cellular immune deficiencies, hypogammaglobulinemic and dysgammaglobulinemic states. Measles inclusion body encephalitis (MIBE), pneumonitis and death as a direct consequence of disseminated measles vaccine virus infection has been reported in severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. M-M-R<sup>®</sup> II is recommended for asymptomatic HIV-infected individuals.<sup>3,9</sup> M-M-R<sup>®</sup> II is not normally recommended for symptomatic HIV-infected individuals because safety and immunogenicity data are not yet available. If there is a known exposure to measles, measles-immune globulin (IG) should be given within 6 days whether or not the individual has been vaccinated, although the efficacy of IG for passive immunoprophylaxis of measles in HIV-infected individuals is uncertain.

Individuals with a family history of congenital or hereditary immunodeficiency, until the immune competence of the potential vaccine recipient is demonstrated.

## WARNINGS AND PRECAUTIONS

**Severe allergic reactions including anaphylaxis can occur after administration of M-M-R<sup>®</sup> II (see Post-Market Adverse Drug Reactions).**

### General

Administer M-M-R<sup>®</sup> II subcutaneously; **do not give intravascularly.**

Adequate treatment provisions including epinephrine injection (1:1000) should be available for immediate use in case an anaphylactic or anaphylactoid reaction occurs.

Due caution should be employed in administration of M-M-R<sup>®</sup> II to persons with individual or family histories of convulsions, a history of cerebral injury or any other condition in which stress due to fever should be avoided. The physician should be alert to the temperature elevation which may occur 5 to 12 days following vaccination (see ADVERSE REACTIONS).

Children and young adults who are known to be infected with human immunodeficiency viruses and are not immunosuppressed may be vaccinated. However, the vaccinees who are infected with HIV should be monitored closely for vaccine-preventable diseases because immunization may be less effective than for uninfected persons<sup>10,11</sup> (see CONTRAINDICATIONS).

Excretion of small amounts of the live attenuated rubella virus from the nose or throat has occurred in the majority of susceptible individuals 7 to 28 days after vaccination. There is no confirmed evidence to indicate that such virus is transmitted to susceptible persons who are in contact with the vaccinated individuals. Consequently, transmission, while accepted as a theoretical possibility, is not regarded as a significant risk.<sup>3</sup> However, transmission of the rubella vaccine virus to infants via breast milk has been documented (see Nursing Women).

There are no reports of transmission of live attenuated measles or mumps viruses from vaccinees to susceptible contacts.

This product contains a trace amount ( $<1 \times 10^{-6}$  mg/dose) of albumin, a derivative of human blood. Although there is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD) or its variant (vCJD), no cases of transmission of CJD, vCJD, or viral diseases have ever been identified that were associated with the use of albumin.

As for any vaccine, vaccination with M-M-R<sup>®</sup> II may not result in protection in 100% of vaccinees.

### Hematologic

#### Thrombocytopenia

Individuals with current thrombocytopenia may develop more severe thrombocytopenia following vaccination. In addition, individuals who experienced thrombocytopenia with the first dose of M-M-R<sup>®</sup> II (or its component vaccines) may develop thrombocytopenia with repeat

doses.<sup>12</sup> Serologic status may be evaluated to determine whether or not additional doses of vaccine are needed. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases (see ADVERSE REACTIONS).

### **Immune and Hypersensitivity**

Live measles vaccine and live mumps vaccine are produced in chick embryo cell culture. Persons with a history of anaphylactic, anaphylactoid or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving vaccines containing traces of chick embryo antigen. The potential risk to benefit ratio should be carefully evaluated before considering vaccination in such cases. Such individuals may be vaccinated with extreme caution, having adequate treatment on hand should a reaction occur.<sup>3</sup>

According to the National Advisory Committee on Immunization (NACI), "anaphylaxis after measles vaccination is rare. It has been reported both in people with anaphylactic hypersensitivity to eggs and in those with no history of egg allergy. In some of these instances it is hypersensitivity to gelatin that is responsible for the anaphylactic reaction. As well, allergy to other components of the vaccine, such as neomycin, has been hypothesized but not proven. The minute quantity of egg proteins contained in measles-mumps-rubella vaccines (MMR) seems to be insufficient to cause an allergic reaction in egg-allergic people."<sup>41</sup>

"Several studies have reported uneventful routine MMR immunization in egg-allergic people and in those with positive MMR skin tests, whereas others have reported occasional adverse reactions despite the use of MMR skin testing and graded challenge vaccination. Therefore the use of skin testing with MMR vaccines in egg-allergic individuals is no longer recommended."<sup>41</sup>

"In view of the cumulative data indicating the safety of MMR immunization in people with a history of anaphylactic hypersensitivity to hens' eggs and the lack of evidence of the predictive value of MMR skin testing, NACI does not recommend routine MMR skin testing or any special precaution in these individuals. As for all vaccines, NACI recommends immunization by personnel with the capability and facilities to manage adverse events following immunization such as anaphylaxis."<sup>41</sup>

### **Special Populations**

#### **Pregnant Women**

Animal reproduction studies have not been conducted with M-M-R<sup>®</sup> II. It is also not known whether M-M-R<sup>®</sup> II can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Therefore, the vaccine should not be administered to pregnant females; furthermore, pregnancy should be avoided for three months following vaccination (see CONTRAINDICATIONS).

In counseling women who are inadvertently vaccinated when pregnant or who become pregnant within 3 months of vaccination, the physician should be aware of the following: (1) In a 10-year

survey involving over 700 pregnant women who received rubella vaccine within 3 months before or after conception (of whom 189 received the Wistar RA 27/3 strain), none of the newborns had abnormalities compatible with congenital rubella syndrome;<sup>13</sup> (2) Mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion. Although mumps vaccine virus has been shown to infect the placenta and fetus,<sup>14</sup> there is no good evidence that it causes congenital malformations in humans; and (3) Reports have indicated that contracting of wild-type measles during pregnancy enhances fetal risk. Increased rates of spontaneous abortion, stillbirth, congenital defects and prematurity have been observed subsequent to infection with wild-type measles during pregnancy. There are no adequate studies of the attenuated (vaccine) strain of measles virus in pregnancy. However, it would be prudent to assume that the vaccine strain of virus is also capable of inducing adverse fetal effects.

### Nursing Women

It is not known whether measles or mumps vaccine virus is secreted in human milk. Recent studies have shown that lactating postpartum women immunized with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants.<sup>15</sup> In the infants with serological evidence of rubella infection, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella.<sup>16,17</sup> Caution should be exercised when M-M-R<sup>®</sup> II is administered to a nursing woman.

### Pediatric (<12 months)

Safety and effectiveness of measles vaccine in infants below the age of 6 months have not been established. Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established.

### **Monitoring & Laboratory Tests**

It has been reported that live attenuated measles, mumps and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin test is to be done, it should be administered either before or simultaneously with M-M-R<sup>®</sup> II.

Children under treatment for tuberculosis have not experienced exacerbation of the disease when immunized with live measles virus vaccine;<sup>18</sup> no studies have been reported to date of the effect of measles virus vaccines on untreated tuberculous children.

## **ADVERSE REACTIONS**

A clinical trial comparing the safety and immunogenicity of M-M-R<sup>®</sup> II manufactured with recombinant human albumin (rHA) and M-M-R<sup>®</sup> II manufactured with human serum albumin (HSA) was conducted in 1279 children. Clinical follow-up was obtained for 634/641 (98.9%) subjects who received M-M-R<sup>®</sup> II with rHA and 632/638 (99.1%) subjects who received M-M-R<sup>®</sup> II with HSA.



The number and percentage of subjects who reported specific systemic adverse experiences with an incidence of  $\geq 1\%$  in either treatment group during Days 1 to 42 postvaccination are presented by body system and treatment group in Table 1.

**Table 1 – Number (%) of Subjects with Specific Systemic Clinical Adverse Experiences (Incidence  $\geq 1\%$  in One or More Treatment Groups) by Body System (Days 1 to 42 Following Vaccination)**

	M-M-R <sup>®</sup> II With rHA (N=641)				M-M-R <sup>®</sup> II With HSA (N=638)			
	All Adverse Experiences		VR		All Adverse Experiences		VR	
	n	(%)	n	(%)	n	(%)	n	(%)
Number of subjects	641				638			
Number of subjects without follow-up	7				6			
Number of subjects with follow-up	634				632			
Number (%) of subjects with one or more systemic adverse experiences	469	(74.0)			465	(73.6)		
Number (%) of subjects with no systemic adverse experience	165	(26.0)			167	(26.4)		
<b>Ear and Labyrinth Disorders</b>	<b>11</b>	<b>(1.7)</b>			<b>7</b>	<b>(1.1)</b>		
Ear pain	7	(1.1)			2	(0.3)		
<b>Eye Disorders</b>	<b>27</b>	<b>(4.3)</b>			<b>14</b>	<b>(2.2)</b>	<b>4</b>	<b>(0.6)</b>
Conjunctivitis	22	(3.5)			10	(1.6)	2	(0.3)
<b>Gastrointestinal Disorders</b>	<b>99</b>	<b>(15.6)</b>	<b>8</b>	<b>(1.3)</b>	<b>110</b>	<b>(17.4)</b>	<b>14</b>	<b>(2.2)</b>
Constipation	5	(0.8)			7	(1.1)		
Diarrhea NOS	45	(7.1)	4	(0.6)	41	(6.5)	6	(0.9)
Loose stools	8	(1.3)	1	(0.2)	9	(1.4)	2	(0.3)
Teething	11	(1.7)			9	(1.4)		
Vomiting NOS	35	(5.5)	3	(0.5)	41	(6.5)	5	(0.8)
<b>General Disorders and Administration Site Conditions</b>	<b>158</b>	<b>(24.9)</b>	<b>61</b>	<b>(9.6)</b>	<b>149</b>	<b>(23.6)</b>	<b>69</b>	<b>(10.9)</b>
Pain NOS	10	(1.6)	4	(0.6)	4	(0.6)	2	(0.3)
Pyrexia	144	(22.7)	56	(8.8)	138	(21.8)	63	(10.0)
<b>Immune System Disorders</b>	<b>6</b>	<b>(0.9)</b>			<b>8</b>	<b>(1.3)</b>	<b>1</b>	<b>(0.2)</b>
Hypersensitivity NOS	2	(0.3)			8	(1.3)	1	(0.2)
<b>Infections and Infestations</b>	<b>279</b>	<b>(44.0)</b>	<b>15</b>	<b>(2.4)</b>	<b>256</b>	<b>(40.5)</b>	<b>17</b>	<b>(2.7)</b>
Croup infectious	8	(1.3)			5	(0.8)		
Ear infection NOS	23	(3.6)	1	(0.2)	18	(2.8)	1	(0.2)
Gastroenteritis NOS	11	(1.7)	1	(0.2)	12	(1.9)		
Nasopharyngitis	80	(12.6)	4	(0.6)	84	(13.3)	5	(0.8)
Otitis media NOS	79	(12.5)	1	(0.2)	65	(10.3)	3	(0.5)
Sinusitis NOS	5	(0.8)			13	(2.1)		
Upper respiratory tract infection NOS	98	(15.5)	3	(0.5)	87	(13.8)	5	(0.8)
Upper respiratory tract infection viral NOS	8	(1.3)			3	(0.5)		
Viral infection NOS	25	(3.9)	2	(0.3)	17	(2.7)		
Viral rash NOS	14	(2.2)	3	(0.5)	14	(2.2)	5	(0.8)
<b>Injury, Poisoning and Procedural Complications</b>	<b>33</b>	<b>(5.2)</b>			<b>25</b>	<b>(4.0)</b>	<b>1</b>	<b>(0.2)</b>
Arthropod bite	15	(2.4)			8	(1.3)	1	(0.2)
<b>Metabolism and Nutrition Disorders</b>	<b>7</b>	<b>(1.1)</b>			<b>5</b>	<b>(0.8)</b>		

	M-M-R <sup>®</sup> II With rHA (N=641)				M-M-R <sup>®</sup> II With HSA (N=638)			
	All Adverse Experiences		VR		All Adverse Experiences		VR	
	n	(%)	n	(%)	n	(%)	n	(%)
<b>Nervous System Disorders</b>	<b>7</b>	<b>(1.1)</b>	<b>1</b>	<b>(0.2)</b>	<b>6</b>	<b>(0.9)</b>	<b>3</b>	<b>(0.5)</b>
<b>Psychiatric Disorders</b>	<b>53</b>	<b>(8.4)</b>	<b>27</b>	<b>(4.3)</b>	<b>48</b>	<b>(7.6)</b>	<b>26</b>	<b>(4.1)</b>
Insomnia	7	(1.1)	1	(0.2)	0	(0.0)		
Irritability	49	(7.7)	27	(4.3)	47	(7.4)	25	(4.0)
<b>Respiratory, Thoracic and Mediastinal Disorders</b>	<b>109</b>	<b>(17.2)</b>	<b>4</b>	<b>(0.6)</b>	<b>121</b>	<b>(19.1)</b>	<b>11</b>	<b>(1.7)</b>
Cough	41	(6.5)	1	(0.2)	43	(6.8)	1	(0.2)
Nasal congestion	22	(3.5)			30	(4.7)	3	(0.5)
Rhinitis NOS	6	(0.9)			12	(1.9)	1	(0.2)
Rhinorrhoea	41	(6.5)	3	(0.5)	41	(6.5)	4	(0.6)
Wheezing	15	(2.4)	1	(0.2)	12	(1.9)	1	(0.2)
<b>Skin and Subcutaneous Tissue Disorders</b>	<b>162</b>	<b>(25.6)</b>	<b>50</b>	<b>(7.9)</b>	<b>142</b>	<b>(22.5)</b>	<b>41</b>	<b>(6.5)</b>
Dermatitis diaper	31	(4.9)	1	(0.2)	32	(5.1)	1	(0.2)
Eczema	10	(1.6)			15	(2.4)		
Heat rash	25	(3.9)	4	(0.6)	8	(1.3)	1	(0.2)
Rash morbilliform	20	(3.2)	20	(3.2)	11	(1.7)	10	(1.6)
Rash NOS	53	(8.4)	20	(3.2)	47	(7.4)	19	(3.0)
Urticaria NOS	8	(1.3)	3	(0.5)	8	(1.3)	3	(0.5)

Percentages are calculated based on the number of subjects with follow-up.  
Although a subject may have had 2 or more systemic adverse experiences, the subject is counted only once in the overall total.  
Adverse experience terms are from MedDRA Version 6.0.  
N=Number of subjects vaccinated in each treatment group.  
VR=Vaccine-related. Entries in this column refer to the number (%) of subjects with systemic adverse experiences that were determined by the investigator to be possibly, probably, or definitely related to the vaccine.  
rHA=Recombinant human albumin.  
HSA=Human serum albumin.

### **Potential undesirable effects**

Additional clinical and post marketing data from previous formulations of monovalent and of the combined measles, mumps, and rubella vaccines manufactured by Merck & Co., Inc. without regard to causality or frequency are available and are summarized below. These data were reported based on more than 400 million doses distributed worldwide. Potential undesirable effects already provided in the previous section (related to the clinical experience with M-M-R<sup>®</sup> II with rHA) are excluded from the data provided below.

### **Common**

Burning and/or stinging of short duration at the injection site.

### **Occasional**

#### **Body as a whole**

Fever (38.3°C or higher).

**Skin**

Rash, or measles-like rash, usually minimal but may be generalized. Generally, fever, rash, or both appear between the 5th and the 12th day.

**Rare****Body as a whole**

Mild local reactions such as erythema, induration and tenderness; sore throat, malaise, atypical measles, syncope, irritability.

**Cardiovascular**

Vasculitis.

**Digestive**

Parotitis, nausea, vomiting, diarrhea.

**Hematologic/Lymphatic**

Regional lymphadenopathy, thrombocytopenia, purpura.

**Hypersensitivity**

Allergic reactions such as wheal and flare at injection site, anaphylaxis and anaphylactoid reactions, as well as related phenomena such as angioneurotic edema (including peripheral or facial edema) and bronchial spasm, urticaria in individuals with or without an allergic history.

**Musculoskeletal**

Arthralgia and/or arthritis (usually transient and rarely chronic [see below **Other**]), myalgia.

**Nervous/Psychiatric**

Febrile convulsions in children, afebrile convulsions or seizures, headache, dizziness, paresthesia, polyneuritis, polyneuropathy, Guillain-Barré syndrome, ataxia, acute disseminated encephalomyelitis (ADEM), transverse myelitis, aseptic meningitis (see below), measles inclusion body encephalitis (MIBE) (see CONTRAINDICATIONS).

**Respiratory System**

Pneumonia, pneumonitis (see CONTRAINDICATIONS), cough, rhinitis.

**Skin**

Erythema multiforme, Stevens-Johnson syndrome, Henoch-Schönlein purpura, Acute Hemorrhagic Edema of Infancy, vesiculation at injection site, swelling, pruritus.

**Special Senses**

Forms of optic neuritis, including retrobulbar neuritis, papillitis, and retinitis; ocular palsies, otitis media, nerve deafness, conjunctivitis.

## **Urogenital**

Epididymitis, orchitis.

## **Other**

Death from various, and in some cases unknown, causes has been reported rarely following vaccination with measles, mumps, and rubella vaccines; however, a causal relationship has not been established in healthy individuals (see CONTRAINDICATIONS). No deaths or permanent sequelae were reported in a published post-marketing surveillance study in Finland involving 1.5 million children and adults who were vaccinated with M-M-R<sup>®</sup> II during 1982 to 1993.<sup>20</sup>

## **Arthralgia and/or arthritis**

Arthralgia and/or arthritis (usually transient and rarely chronic), and polyneuritis are features of infection with wild-type rubella and vary in frequency and severity with age and sex, being greatest in adult females and least in prepubertal children.

Chronic arthritis has been associated with wild-type rubella infection and has been related to persistent virus and/or viral antigen isolated from body tissues. Only rarely have vaccine recipients developed chronic joint symptoms.

Following vaccination in children, reactions in joints are uncommon and generally of brief duration. In women, incidence rates for arthritis and arthralgia are generally higher than those seen in children (children: 0–3%; women: 12–20%),<sup>19</sup> and the reactions tend to be more marked and of longer duration. Symptoms may persist for a matter of months or on rare occasions for years. In adolescent girls, the reactions appear to be intermediate in incidence between those seen in children and in adult women. Even in older women (35 to 45 years), these reactions are generally well tolerated and rarely interfere with normal activities.<sup>19</sup>

## **Post-Market Adverse Drug Reactions**

### **Subacute Sclerosing Panencephalitis (SSPE)**

There have been reports of SSPE in children who did not have a history of infection with wild-type measles but did receive measles vaccine. Some of these cases may have resulted from unrecognized measles in the first year of life or possibly from the measles vaccination. Based on estimated nationwide measles vaccine distribution, the association of SSPE cases to measles vaccination is about one case per million vaccine doses distributed. This is far less than the association with infection with wild-type measles, 6–22 cases of SSPE per million cases of measles. The results of a retrospective case-controlled study conducted by the Centers for Disease Control and Prevention suggest that the overall effect of measles vaccine has been to protect against SSPE by preventing measles with its inherent higher risk of SSPE.<sup>21</sup>

### **Aseptic Meningitis**

Cases of aseptic meningitis have been reported following measles, mumps, and rubella vaccination. A causal relationship between the Urabe strain of mumps vaccine and aseptic meningitis has been shown. Although a temporal association has been observed between the

administration of M-M-R<sup>®</sup> II and rare cases of aseptic meningitis, there is no laboratory-confirmed evidence to link Jeryl Lynn<sup>®</sup> mumps vaccine to aseptic meningitis.

#### Encephalitis/encephalopathy

Encephalitis/encephalopathy have been reported approximately once for every 3 million doses of the measles, mumps, and rubella vaccine manufactured by Merck & Co., Inc.<sup>19</sup> Since 1978, post-marketing surveillance indicates that serious adverse events such as encephalitis and encephalopathy continue to be rarely reported. The risk of such serious neurological disorders following live measles virus vaccine administration remains far less than that for encephalitis and encephalopathy with wild-type measles (one per one thousand reported cases).

In severely immunocompromised individuals inadvertently vaccinated with measles-containing vaccine, measles inclusion body encephalitis, pneumonitis, and fatal outcome as a direct consequence of disseminated measles vaccine virus infection have been reported (see CONTRAINDICATIONS); disseminated mumps and rubella vaccine virus infection have also been reported.

#### Panniculitis

Panniculitis has been reported rarely following administration of measles vaccine.<sup>22</sup>

Cases of severe allergic reaction including anaphylaxis have been reported shortly after the administration of M-M-R<sup>®</sup> II.

## DRUG INTERACTIONS

Administration of immune globulins concurrently with M-M-R<sup>®</sup> II may interfere with the expected immune response. Vaccination should be deferred for 3 months or longer following administration of immune globulin (human) and blood or plasma transfusions.

## DOSAGE AND ADMINISTRATION

### Recommended Dose and Dosage Adjustment

The dosage of M-M-R<sup>®</sup> II is the same for all persons.

After suitably cleansing the immunization site, inject the total volume of the single-dose vial (about 0.5 mL) or 0.5 mL of the 10-dose vial of reconstituted vaccine subcutaneously, preferably into the outer aspect of the upper arm.

### Revaccination

Children vaccinated when younger than 12 months of age should be revaccinated (two additional doses) after reaching 12 months of age (see INDICATIONS AND CLINICAL USE).

A number of national, governmental vaccine authorities, the American Academy of Pediatrics (AAP), the Advisory Committee on Immunization Practices (ACIP) and the National Advisory Committee on Immunization (NACI) have recommended guidelines for routine revaccination and to help control measles and mumps outbreaks.<sup>†,3,5,23,24,25</sup>

A second dose of measles-containing vaccine should be deferred for HIV-infected persons with moderate or advanced immunodeficiency. Measles revaccination may still be appropriate for HIV-infected persons with moderate immunodeficiency if, there is a high risk of wild strain measles in the local community, or travel to an area where measles is endemic.<sup>9</sup>

If the prevention of sporadic measles outbreaks is the sole objective, revaccination with a measles-containing vaccine should be considered (see appropriate Product Monograph). If concern also exists about immune status regarding mumps or rubella, revaccination with appropriate mumps- or rubella-containing vaccine should be considered after consulting the appropriate Product Monographs. Unnecessary doses of a vaccine are best avoided by ensuring that written documentation of vaccination is preserved and a copy given to each vaccinee's parent or guardian.

#### **Non-Pregnant Adolescent and Adult Females**

Immunization of susceptible non-pregnant adolescent and adult females of childbearing age with live attenuated rubella virus vaccine is indicated if certain precautions are observed (see WARNINGS AND PRECAUTIONS, Pregnant Women). In view of the importance of protecting this age group against rubella, reasonable precautions in a rubella immunization program include asking females if they are pregnant, excluding those who say they are, and explaining the theoretical risks to the others. Vaccinating susceptible postpubertal females confers individual protection against subsequently acquiring rubella infection during pregnancy, which in turn prevents infection of the fetus and consequent congenital rubella injury.<sup>26</sup>

Women of childbearing age should be advised not to become pregnant for three months after vaccination and should be informed on the reasons for this precaution.<sup>26</sup>

It is recommended, when feasible, that rubella susceptibility be determined by serologic testing prior to immunization. Since serologic testing is expensive and not always accurate, rubella vaccination of a woman who is not known to be pregnant and has no history of vaccination is justifiable without serologic testing. If immune, as evidenced by a specific rubella antibody titer of 1:8 or greater (hemagglutination-inhibition test), vaccination is unnecessary. Congenital malformations do occur in up to seven percent of all live births.<sup>27</sup> Their chance appearance after vaccination could lead to misinterpretation of the cause, particularly if the prior rubella-immune status of vaccinees is unknown.

---

<sup>†</sup> NOTE: A primary difference among these recommendations is the timing of revaccination: The NACI recommends routine revaccination at least one month after the first dose, or at 18 months, or with entry into daycare or school. The AAP and ACIP recommend routine revaccination at 4 to 6 years of age. In addition, some public health jurisdictions mandate the age for revaccination. The complete text of applicable guidelines should be consulted.<sup>3,5,23,24,25</sup>

Postpubertal females should be informed of the frequent occurrence of generally self-limited arthralgia and/or possible arthritis beginning 2 to 4 weeks after vaccination (see ADVERSE REACTIONS).

### **Postpartum Women**

It has been found convenient in many instances to vaccinate rubella-susceptible women in the immediate postpartum period (see WARNINGS AND PRECAUTIONS, Nursing Women).

### **Use with other Vaccines**

M-M-R<sup>®</sup> II should be given concomitantly, or one month before or after administration of other live attenuated viral vaccines.

In combined clinical studies involving 1107 children 12 to 36 months of age, 680 received varicella vaccine (Oka/Merck) and M-M-R<sup>®</sup> II concomitantly at separate sites and 427 received the vaccines six weeks apart. Seroconversion rates and antibody levels were comparable between the two groups at approximately six weeks postvaccination to each of the virus vaccine components. No differences were noted in adverse reactions reported in those who received varicella vaccine (Oka/Merck) concomitantly with M-M-R<sup>®</sup> II at separate sites and those who received varicella vaccine (Oka/Merck) and M-M-R<sup>®</sup> II at different times.

In a clinical study involving 609 children 12 months to 23 months of age, 305 received varicella vaccine (Oka/Merck), M-M-R<sup>®</sup> II, and Tetramune (*Haemophilus influenzae* type b, diphtheria, tetanus, and pertussis vaccines) concomitantly at separate sites and 304 received M-M-R<sup>®</sup> II and Tetramune given concomitantly at separate sites followed by varicella vaccine (Oka/Merck) 6 weeks later. At six weeks postvaccination, seroconversion rates for measles, mumps, rubella, and varicella were similar between the two groups. Compared to prevaccination GMTs, the six week postvaccination boost in GMTs for *Haemophilus influenzae* type b, diphtheria, tetanus and pertussis was similar between the two groups. GMTs for all antigens were similar except for varicella which was lower when varicella vaccine (Oka/Merck) was administered concomitantly with M-M-R<sup>®</sup> II and Tetramune but within the range of GMTs seen in previous clinical experience when varicella vaccine (Oka/Merck) was administered alone. At 1 year postvaccination, GMTs for measles, mumps, rubella, varicella and *Haemophilus influenzae* type b were similar between the two groups. All three vaccines were well tolerated regardless of whether they were administered concomitantly at separate sites or 6 weeks apart. There were no clinically important differences in reaction rates when the three vaccines were administered concomitantly versus 6 weeks apart.

M-M-R<sup>®</sup> II has been administered concurrently with other vaccines (i.e., live attenuated varicella, DTaP [or DTwP], IPV [or OPV], Hib with or without Hepatitis B vaccine) using separate injection sites and syringes. No impairment of immune response to individual tested vaccine antigens was demonstrated. The type, frequency, and severity of adverse experiences observed with M-M-R<sup>®</sup> II were similar to those seen when each vaccine was given alone.

### Administration

Do not inject M-M-R<sup>®</sup> II intravascularly. **Do not give immune globulin (IG) concurrently with M-M-R<sup>®</sup> II** (see DRUG INTERACTIONS).

**CAUTION:** A sterile syringe free of preservatives, antiseptics, and detergents should be used for each injection and/or reconstitution of the vaccine because these substances may inactivate the live virus vaccine. A 25 gauge, 15 mm needle is recommended.

#### Prior to Administration:

Inspect the reconstituted solution for particulate matter and discoloration. The reconstituted solution should be **clear yellow**. Should complete dissolution not occur within two minutes, do not use and return for reimbursement.

It is important to use a separate sterile syringe and needle for each individual patient to prevent transmission of hepatitis B and other infectious agents from one person to another.

### Reconstitution

#### Prior to Reconstitution:

Check the appearance of the content of each vial of vaccine. The content should be a light yellow solid mass ("plug") of powder which fills the bottom of each vial.

To reconstitute, use only the diluent supplied, since it is free of preservatives or other antiviral substances which might inactivate the vaccine.

First withdraw the entire volume of diluent (0.7 mL) into the syringe to be used for reconstitution. Inject all the diluent in the syringe into the vial of lyophilized vaccine, and agitate to mix thoroughly. Withdraw the entire contents into a syringe and inject the total volume of restored vaccine subcutaneously.

Vial Size	Volume of Diluent to be Added to Vial	Number of Doses Available
Single-dose	0.7 mL	1 (0.5 mL/dose)

### OVERDOSAGE

Overdosage has been reported rarely and was not associated with any serious adverse events.

For management of a suspected overdose, contact your regional Poison Control Centre.
--



## **ACTION AND CLINICAL PHARMACOLOGY**

M-M-R<sup>®</sup> II is a live, attenuated vaccine for immunization against measles (rubeola), mumps, and rubella (German measles).

Measles, mumps, and rubella are three common childhood diseases, caused by measles virus, mumps virus (paramyxoviruses), and rubella virus (togavirus), respectively, that may be associated with serious complications and/or death. For example, pneumonia and encephalitis are caused by measles. Mumps is associated with aseptic meningitis, deafness and orchitis; and rubella during pregnancy may cause congenital rubella syndrome in the infants of infected mothers.

Clinical studies of 284 triple seronegative children, 11 months to 7 years of age, demonstrated that M-M-R<sup>®</sup> II is highly immunogenic and generally well tolerated. In these studies, a single injection of the vaccine induced measles hemagglutination-inhibition (HI) antibodies in 95%, mumps neutralizing antibodies in 96%, and rubella HI antibodies in 99% of susceptible persons. However, a small percentage (1–5%) of vaccinees may fail to seroconvert after the primary dose.

The RA 27/3 rubella strain in M-M-R<sup>®</sup> II elicits higher immediate post-vaccination HI, complement-fixing and neutralizing antibody levels than other strains of rubella vaccine<sup>28–34</sup> and has been shown to induce a broader profile of circulating antibodies including anti-theta and anti-iota precipitating antibodies.<sup>35,36</sup> The RA 27/3 rubella strain immunologically simulates natural infection more closely than other rubella vaccine viruses.<sup>36–38</sup> The increased levels and broader profile of antibodies produced by RA 27/3 strain rubella virus vaccine appear to correlate with greater resistance to subclinical reinfection with the wild virus,<sup>36,38–40</sup> and provide greater confidence for lasting immunity.

Following vaccination, antibodies associated with protection can be measured by neutralization assays, HI, or ELISA (enzyme linked immunosorbent assay) tests. Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination.<sup>19</sup>

## **STORAGE AND STABILITY**

During shipment, to ensure that there is no loss of potency, M-M-R<sup>®</sup> II must be maintained at a temperature between -50°C and +8°C. Use of dry ice may subject M-M-R<sup>®</sup> II to temperatures colder than -50°C.

Before reconstitution, M-M-R<sup>®</sup> II should be stored refrigerated at a temperature of 2°C to 8°C. The vaccine may also be stored in a freezer at temperatures above -50°C; if subsequently transferred to a refrigerator, the vaccine may be placed back in the freezer.

M-M-R<sup>®</sup> II can be administered provided total (cumulative multiple excursions) time out of refrigeration (prior to reconstitution, at temperatures between 8°C and 25°C) does not exceed 6 hours. These are not, however, recommendations for storage.

Protect the vaccine from light at all times, since such exposure may inactivate the viruses.

Before reconstitution, store the vial of lyophilized vaccine at 2°C to 8°C or colder (above -50°C). The diluent may be stored in the refrigerator with the lyophilized vaccine or separately at room temperature.

### **Reconstituted Solutions**

**To maintain the potency, it is imperative that only the sterile diluent for Merck Sharp & Dohme Corp., live, attenuated virus vaccines (Sterile Water) be used for reconstitution and injection.**

Use **AS SOON AS POSSIBLE** after reconstitution. Store reconstituted vaccine in the vaccine vial in a dark place at 2°C to 8°C. Discard if not used **within 8 hours**.

## **DOSAGE FORMS, COMPOSITION AND PACKAGING**

### **Dosage Forms**

M-M-R<sup>®</sup> II (measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.) is supplied as a sterile, lyophilized, light yellow compact crystalline plug in a single-dose vial.

The diluent (Sterile Diluent for Merck Sharp & Dohme Corp., live, attenuated virus vaccines) is a sterile, clear, colourless fluid supplied separately in a single-dose vial.

After reconstitution, M-M-R<sup>®</sup> II is a clear yellow liquid.

### **Composition**

When reconstituted as directed, each single dose (0.5 mL) contains:

#### **Active Ingredients**

Measles virus, Enders' Edmonston strain (live, attenuated)	not less than 1,000 CCID <sub>50</sub> *
Mumps virus, Jeryl Lynn <sup>®</sup> (B level) strain (live, attenuated)	not less than 5,000 CCID <sub>50</sub>
Rubella virus, Wistar RA 27/3 strain (live, attenuated)	not less than 1,000 CCID <sub>50</sub>

\* 50% cell culture infectious dose

## Other Ingredients

<i>Excipients</i>	Maximum Quantity/Dose
Sorbitol	14.5 mg
Hydrolyzed gelatin	14.5 mg
Medium 199 with Hank's salts	3.3 mg
Sodium phosphate monobasic	3.1 mg
Sodium phosphate dibasic (anhydrous)	2.2 mg
Sucrose	1.9 mg
Sodium bicarbonate	0.5 mg
Minimum Essential Medium, Eagle	0.1 mg
Potassium phosphate dibasic (anhydrous)	30 µg
Neomycin	25 µg
Monosodium L-glutamate monohydrate	20 µg
Potassium phosphate monobasic	20 µg
Phenol red	3.4 µg
Water for injection	To volume

  

<i>Manufacturing Process Residuals</i>	
Recombinant human albumin	≤0.3 mg
Fetal bovine serum	<1 ppm

The vaccine contains no preservative.

The diluent is sterile water for injection.

## **Packaging**

M-M-R<sup>®</sup> II is supplied in 3 mL single-dose Type I glass vials. Each vial contains one dose of lyophilized vaccine (approximately 0.5 mL when reconstituted as directed).

The diluent (0.7 mL) is supplied separately in 3 mL single-dose Type I glass vials.

The container closure systems of M-M-R<sup>®</sup> II and the diluent are free of latex.

M-M-R<sup>®</sup> II is available in packages of 10 single-dose vials. The diluent is also available in packages of 10 single-dose vials.

## PART II: SCIENTIFIC INFORMATION

### PHARMACEUTICAL INFORMATION

#### Drug Substance

Proper name: measles, mumps, and rubella virus vaccine, live, attenuated, Merck Std.

### CLINICAL TRIALS

#### Study demographics and trial design

Protocol 009 (M-M-R<sup>®</sup> II [measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.] with rHA replacement study) was designed to (1) demonstrate that the antibody response rates to measles, mumps, and rubella among children who received M-M-R<sup>®</sup> II manufactured with rHA will be similar to the antibody response rates among children who receive M-M-R<sup>®</sup> II manufactured with HSA; (2) to demonstrate that M-M-R<sup>®</sup> II manufactured with rHA will induce acceptable antibody response rates to measles, mumps, and rubella; and (3) to demonstrate that M-M-R<sup>®</sup> II with rHA will be generally well tolerated. This was a double-blind (using in-house blinding procedures), randomized, comparative multicenter study of 1282 healthy children at 12 to 18 months of age. Eligible subjects were randomized to receive either an investigational formulation of M-M-R<sup>®</sup> II manufactured with rHA or currently licensed M-M-R<sup>®</sup> II manufactured with HSA. In order to determine if any rHA manufacturing residual would elicit an immune reaction, certain adverse experiences of special interest (AESI) that are indicative of hypersensitivity reaction were prespecified in the protocol and prompted for on the Vaccination Report Card (VRC). The incidence of injection-site adverse experiences, temperature  $\geq 38.9$  °C ( $\geq 102.0$  °F), oral equivalent or abnormal), non-injection site rashes, other local and systemic adverse experiences were reported for the 42 days (6 weeks) following vaccination. Serum samples were obtained from each subject immediately prior to the vaccination on Day 0, and 6 weeks postvaccination.

The primary endpoints used to assess immunogenicity 6 weeks postvaccination were the antibody response rates for measles, mumps, and rubella, defined as the proportion of subjects who developed serum antibody levels  $>120$  mIU/mL for measles,  $>10.0$  ELISA antibody units/mL for mumps, or  $>10.0$  IU/mL for rubella. The primary analysis of the response rate to measles, mumps, and rubella were based on a per-protocol subject population, which included subjects without protocol violations who had a valid baseline and week 6 titer values for analysis, and whose baseline measles antibody titers were  $<120$  mIU/mL, whose baseline mumps antibody titers were  $<10.0$  ELISA antibody units/mL, and whose baseline rubella antibody titers were  $<10.0$  IU/mL. Both the primary immunogenicity hypotheses of similarity to the control group and for acceptability of antibody responses in recipients of M-M-R<sup>®</sup> II with rHA were satisfied for measles, mumps, and rubella. The 2-sided 90% confidence intervals on the differences in estimated antibody response rates to measles, mumps, and rubella between recipients of M-M-R<sup>®</sup> II with rHA and recipients of M-M-R<sup>®</sup> II with HSA all excluded a decrease of 5 percentage points or more and thus support a conclusion of similarity between the

2 treatment groups for each antigen. The lower bounds of the 2-sided 95% CI for each of the 3 antibody response rates in recipients of M-M-R<sup>®</sup> II with rHA were all greater than 90%, supporting the conclusion of acceptable antibody response rates. Measles, mumps, and rubella GMTs measured 6 weeks postvaccination were comparable between the two treatment groups. Summaries of the immunogenicity results measured in the 2 treatment groups are provided in tables 2 (non-inferiority analysis) and 3 (acceptability analysis).

**Table 2 – Statistical Analysis of Similarity of Measles, Mumps, and Rubella Antibody Responses in Initially Seronegative Subjects (Per-Protocol Analysis)**

Antibody (ELISA)	Parameter	M-M-R <sup>®</sup> II With rHA (N=641)		M-M-R <sup>®</sup> II With HSA (N=638)		Estimated Difference <sup>†‡</sup> (Percentage Points) (90% CI) <sup>‡</sup>	Similarity Conclusion
		n	Estimated Response <sup>†</sup>	n	Estimated Response <sup>†</sup>		
Measles	% ≥120 mIU/mL	531	98.3%	498	98.8%	-0.5% (-1.9%, 0.8%)	Similar <sup>§</sup>
Mumps	% ≥10.0 ELISA antibody units/mL	563	99.4%	533	97.9%	1.5% (0.4%, 2.8%)	Similar <sup>§</sup>
Rubella	% ≥10.0 IU/mL	572	99.6%	543	99.6%	0.0% (-0.8%, 0.8%)	Similar <sup>§</sup>

<sup>†</sup> Responses and their difference were based on a statistical analysis model adjusting for study centers.  
<sup>‡</sup> [M-M-R<sup>®</sup> II with rHA] - [M-M-R<sup>®</sup> II with HSA].  
<sup>§</sup> A lower bound of 90% confidence interval (CI) on the difference excluding a decrease of 5 percentage points or more implies the difference is statistically significantly less than the prespecified clinically relevant decrease of 5 percentage points and allows for a conclusion of similarity (non-inferiority). The associated 1-sided p-value for each test is <0.001 (a p-value ≤0.05 implies that the difference is statistically significantly less than the prespecified difference of 5 percentage points).  
 N=Number of subjects vaccinated in each treatment group.  
 n=Number of subjects initially seronegative for measles, mumps, and rubella contributing to the per-protocol analyses.  
 rHA=Recombinant human albumin.  
 HSA=Human serum albumin.  
 ELISA=Enzyme-linked immunosorbent assay.

**Table 3 – Statistical Analysis of Acceptability of Measles, Mumps, and Rubella Responses in Initially Seronegative Subjects (Per-Protocol Analysis)**

Antibody (ELISA)	Parameter	M-M-R <sup>®</sup> II With rHA (N=641)		Acceptability Conclusion
		n	Observed Response (95% CI) <sup>†</sup>	
Measles	% ≥120 mIU/mL	531	98.3% (96.8%, 99.2%)	Acceptable <sup>†</sup>
Mumps	% ≥10.0 ELISA antibody units/mL	563	99.5% (98.5%, 99.9%)	Acceptable <sup>†</sup>
Rubella	% ≥10 IU/mL	572	99.7% (98.7%, 100%)	Acceptable <sup>†</sup>

<sup>†</sup> The lower bound of the 95% confidence interval (CI) being >90% implies that the value of the parameter is statistically significantly greater than the prespecified acceptability criterion (90%) and allows for a conclusion of acceptability.  
 N=Number of subjects vaccinated in treatment group.  
 n=Number of subjects initially seronegative for measles, mumps, and rubella contributing to the per-protocol analyses.  
 rHA=Recombinant human albumin.  
 ELISA=Enzyme-linked immunosorbent assay.

For safety evaluation, one or more adverse experiences occurred in 520 (82.0%) recipients of M-M-R<sup>®</sup> II with rHA and in 506 (80.1%) recipients of M-M-R<sup>®</sup> II with HSA. One or more vaccine-related adverse experiences occurred in 308 (48.6%) recipients of M-M-R<sup>®</sup> II with rHA and in 276 (43.7%) recipients of M-M-R<sup>®</sup> II with HSA. Two-hundred twenty-six (35.6%) recipients of M-M-R<sup>®</sup> II with rHA compared with 187 (29.6%) recipients of M-M-R<sup>®</sup> II with HSA reported injection-site adverse experiences that were vaccine-related. Vaccine-related systemic adverse experiences were reported for 139 (21.9%) recipients of M-M-R<sup>®</sup> II with rHA compared to 149 (23.6%) recipients of M-M-R<sup>®</sup> II with HSA. Only 8 subjects (3 recipients of M-M-R<sup>®</sup> II with rHA and 5 recipients of M-M-R<sup>®</sup> II with HSA) experienced a serious adverse experience during the safety follow-up period. None of these 8 serious adverse experiences was determined by the investigator to be vaccine-related (see ADVERSE REACTIONS). No subjects died during the study and no subjects were discontinued from the study due to an adverse experience.

The two treatment groups were generally comparable in terms of the incidence rates of adverse experiences, although a significantly higher proportion of subjects who received M-M-R<sup>®</sup> II with rHA reported an injection site adverse experience compared with those who received M-M-R<sup>®</sup> II with HSA. The incidence rates of these local reactions were found to be within the historical ranges observed in previous M-M-R<sup>®</sup> II studies and are thought to be related to variability between lots. Moreover, incidence rates of potential hypersensitivity reactions (AESI) were well balanced between the 2 treatment groups and no subjects in either treatment group had detectable antibody to albumin at baseline or 6 weeks postvaccination.

Overall, the study supports the replacement of HSA with rHA in the manufacturing of viral bulks for M-M-R<sup>®</sup> II based on the following similar seroconversion rates for measles, mumps, and rubella induced by M-M-R<sup>®</sup> II manufactured with rHA compared with M-M-R<sup>®</sup> II manufactured with HSA. M-M-R<sup>®</sup> II with rHA is generally well tolerated and has safety and tolerability profiles comparable to those of M-M-R<sup>®</sup> II with HSA, the currently licensed vaccine.

The original trivalent measles, mumps and rubella vaccine, M-M-R<sup>®</sup>, was first licensed in the United States in 1971 and in Canada in 1972. This formulation contained the HPV-77 DE strain of live rubella virus, also used in the monovalent rubella virus vaccine (MERUVAX<sup>®</sup>). In developing M-M-R<sup>®</sup> II, the rubella component of M-M-R<sup>®</sup> (HPV-77 DE) was exchanged with the Wistar RA 27/3 attenuated rubella strain. M-M-R<sup>®</sup> was subsequently discontinued, and M-M-R<sup>®</sup> II (Wistar RA 27/3) was licensed in the United States in 1978 and in Canada in 1979. The Wistar RA 27/3 attenuated rubella strain is cultured in human diploid fibroblasts and was developed by Plotkin in 1965. Comparative studies using the 2 rubella vaccine virus strains showed that RA 27/3 induced stronger rubella-specific immune responses, was associated with lower incidence of adverse experiences, and was associated with lower incidence of breakthrough infection after exposure with wild type rubella virus. Since 1978, the Wistar RA 27/3 strain has been used in place of the HPV-77 DE strain and is the only rubella strain used in all rubella-containing vaccines licensed by Merck Sharp & Dohme Corp.

From 1975 to 1978, 7 studies involving approximately 2,000 subjects (8 months to 27 years of age), were conducted to support the licensure of M-M-R<sup>®</sup> II in many parts of the world,

including Canada. These studies compared the immunogenicity, safety, and tolerability of different combinations of measles, mumps, and rubella live virus vaccines. A summary of 6 out of the 7 studies is included in Table 4.

The seventh study, Protocol 484, compared the immunogenicity and clinical tolerability of M-M-R<sup>®</sup> II Lot 621/C-D763 or M-M-R<sup>®</sup>. One-hundred fifty-five (155) subjects ages 13 months to 27 years of age were enrolled. Of the children with available antibody results, seroconversion was observed in 98% (30/31) of the children receiving HPV-77 DE-containing vaccine and in 100% (47/47) of subjects receiving RA 27/3-containing vaccine.

The most frequent systemic reactions reported in the original study summaries were upper respiratory illness (32%), gastrointestinal illness (23%), irritability (17%), and anorexia (17%). Measles-like rash occurred in 5% of subjects immunized with trivalent vaccine containing the RA 27/3 rubella strain. Seroconversion rates observed at 6 weeks postvaccination among this triple seronegative population were 95% for measles, 96% for mumps, and 99% for rubella.

**Table 4 – Summary of Immunogenicity Results in Children Initially Seronegative to Measles, Mumps, and Rubella Who Received Trivalent Measles, Mumps and Rubella Vaccine Containing the RA 27/3 Rubella Strain**

Study No.	Lot No.	Range	Mean (Year)	N	Antibody Responses among Triple Seronegative Subjects								
					Measles (HI)			Mumps (Neut)			Rubella (Neut)		
					Observed Response	GMT		No. Converting/ No. Seronegative	GMT		No. Converting/ No. Seronegative	GMT	
442	621	10 m to 7 y	3.7	199	100%	(23/23)	99	96%	(22/23)	7	100%	(23/23)	149
443	621	11 m to 8 y	1.7	105 <sup>1</sup>	94%	(65/69) <sup>1</sup>	56	96%	(66/69) <sup>1</sup>	8	100%	(69/69) <sup>1</sup>	133
459	60664	14 m to 4 y	1.5	59	93%	(13/14)	62	93%	(13/14)	17	100%	(14/14)	269
467	621	11 m to 7 y	1.9	137 <sup>2</sup>	95%	(55/58) <sup>2</sup>	71	98%	(57/58) <sup>2</sup>	7	100%	(58/58) <sup>2</sup>	146
511	60664	8 m to 11 y	3.3	50	82%	(9/11)	20	91%	(10/11)	5	100%	(11/11)	226
	60665	11 m to 7 y	3.3	50	80%	(4/5)	25	80%	(4/5)	11	100%	(5/5)	169
	60666	11 m to 11 y	4.2	50	100%	(2/2)	28	100%	(2/2)	8	100%	(2/2)	256
513	60664	12 m to 7 y	1.6	58	94%	(30/32)	74	94%	(30/32)	16	100%	(32/32)	250
	60665	12 m to 4 y	1.6	58	97%	(35/36)	72	97%	(35/36)	23	97%	(35/36)	307
	60666	11 m to 4 y	1.5	59	97%	(33/34)	66	97%	(33/34)	27	97%	(33/34)	256
Totals					95%	(269/284)	63	96%	(272/284)	11	99%	(282/284)	179

HI = Hemagglutination-inhibition.

Neut = Neutralizing.

y = Years.

m = Months.

N = Number vaccinated.

Observed Response = number converted/number initially seronegative.

<sup>1</sup> Three of these subjects were immunized with a 1.0 mL dose of trivalent vaccine containing RA 27/3 strains, 1 subject was triple seronegative prior to immunization and is included in this table.

<sup>2</sup> Twenty subjects were immunized with a 1.0 mL dose of trivalent vaccine containing RA 27/3 strains, 9 subjects were triple seronegative prior to immunization and are included in this table.

## REFERENCES

1. Plotkin SA, Cornfeld D, Ingalls TH. Studies of immunization with living rubella virus: Trials in children with a strain cultured from an aborted fetus. *Am J Dis Child* 1965; 110:381-9.
2. Plotkin SA, Farquhar J, Katz M, Ingalls TH. A new attenuated rubella virus grown in human fibroblasts: Evidence for reduced nasopharyngeal excretion. *Am J Epidemiol* 1967; 86:468-77.
3. National Advisory Committee on Immunization (NACI). Measles vaccine, in: *Canadian Immunization Guide, Seventh Edition, 2006*, p. 228-36.
4. American Academy of Pediatrics. Report of the Committee on Infectious Disease. Evanston, Ill., AAP, 1982, p.136-7.
5. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Measles, mumps, and rubella – vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps. *MMWR* 1998; 47(RR-8):1-57.
6. Jong EC. *The Travel and Tropical Medicine Manual*. W.B. Sanders Company, 1987; 12-16.
7. Committee on Immunization, Council of Medical Societies, American College of Physicians. *Guide for Adult Immunization, First Edition*. Phila., PA, 1985.
8. National Advisory Committee on Immunization (NACI). Recent administration of human immune globulin products, in: *Canadian Immunization Guide, Seventh Edition, 2006*, p. 53.
9. National Advisory Committee on Immunization (NACI). Interim advisory on measles revaccination of persons with acquired immunodeficiency syndrome (AIDS). *CCDR* 1996; 22(14):116-7.
10. Centers for Disease Control. Immunization of children infected with human T-lymphotropic virus type III/lymphadenopathy-associated virus. *Ann Intern Med* 1987; 106(1):75-8.
11. Krasinski K, Borkowsky W, Krugman S. Antibody following measles immunization in children infected with human T-cell lymphotropic virus-type III/lymphadenopathy associated virus (HTLV-III/LAV) [Abstract]. In: *Program and abstracts of the International Conference on Acquired Immunodeficiency Syndrome, Paris, France, June 23-25, 1986*.
12. Vlach V, Forman EN, Miron D, Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. *Pediatrics* 1996; 97(5):738-93.
13. Rubella vaccination during pregnancy - United States, 1971-1981. *MMWR* 1982; 31(35):477-81.
14. Recommendation of the Immunization Practices Advisory Committee (ACIP), Mumps Vaccine. *MMWR* 1982; 31(46):617-20, 625.



15. Losonsky GA, Fishaut JM, Strussenber J, Ogra PL. Effect of immunization against rubella on lactation products. II. Maternal - neonatal interactions. *J Infect Dis* 1982; 145:661-6.
16. Landes RD, Bass JW, Millunchick EW, Oetgen WJ. Neonatal rubella following postpartum maternal immunization. *J Pediatr* 1980; 97:465-7.
17. Lerman SJ. Neonatal rubella following postpartum maternal immunization. *J Pediatr (Letter)* 1981; 98:668.
18. Starr S, Berkovich S. The effect of measles, gamma globulin modified measles, and attenuated measles vaccine on the course of treated tuberculosis in children. *Pediatrics* 1965; 35:97-102.
19. Unpublished data from the files of Merck Sharp & Dohme Research Laboratories.
20. Peltola H, et al. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program. *N Engl J Med.* 1994; 331:1397-1402.
21. CDC, Measles Surveillance, September 1982. Report No.11, p.14.
22. Buck BE, Yang LC, Caleb MH, Green JM, South MA. Measles virus panniculitis subsequent to vaccine administration. *J Pediatr* 1982; 101(3):366-73.
23. National Advisory Committee on Immunization (NACI). Statement on mumps vaccine. *CCDR* 1 Aug 2007; 33(ACS-8):1-10.
24. Recommendations of the Advisory Committee on Immunization Practices (ACIP). General recommendations on immunization. *MMWR* 2006; 55(RR-15):1-48.
25. American Academy of Pediatrics, Committee on Infectious Diseases. Measles: In: *Red Book*, 25th Edition, 2000, p. 385-96.
26. National Advisory Committee on Immunization (NACI). Rubella vaccine, in: *Canadian Immunization Guide*, Seventh Edition, 2006, p. 298-307.
27. McIntosh R, Merritt KK, Richards MR, Samuels MH, Bellows MT. The incidence of congenital malformations: A study of 5,964 pregnancies. *Pediatrics* 1954; 14:505-21.
28. Fogel A, Moshkowitz A, Rannon I, Gerichter ChB. Comparative trials of RA 27/3 and Cendehill rubella vaccines in adult and adolescent females. *Am J Epidemiol* 1971; 93:392-8.
29. Andzhaparidze OG, Desyatskova RG, Chervonski GI, Pryanichnikova LV. Immunogenicity and reactogenicity of live attenuated rubella virus vaccines. *Am J Epidemiol* 1970; 91:527-30.

30. Freestone DS, Reynolds GM, McKinnon JA, Prydie J. Vaccination of schoolgirls against rubella. Assessment of serological status and a comparative trial of Wistar RA 27/3 and Cendehill strain live attenuated rubella vaccines in 13-year-old schoolgirls in Dudley. *Br J Prev Soc Med* 1975; 29:258-61.
31. Grillner L, Hedstrom C-E, Bergstrom H, Forssman L, Rigner A, Lycke E. Vaccination against rubella of newly delivered women. *Scand J Infect Dis* 1973; 5:237-41.
32. Grillner L. Neutralizing antibodies after rubella vaccination of newly delivered women: a comparison between three vaccines. *Scand J Infect Dis* 1975; 7:169-72.
33. Wallace RB, Isacson P. Comparative trial of HPV-77, DE-5 and RA 27/3 live attenuated rubella vaccines. *Am J Dis Child* 1972; 124:536-8.
34. Lalla M, Vesikari T, Virolainen M. Lymphoblast proliferation and humoral antibody response after rubella vaccination. *Clin Exp Immunol* 1973; 15:193-202.
35. LeBouvier GL, Plotkin SA. Precipitin responses to rubella vaccine RA 27/3. *J Infect Dis* 1971; 123:220-3.
36. Horstmann DM. Rubella: The challenge of its control. *J Infect Dis* 1971; 123:640-54.
37. Ogra PL, Kerr-Grant D, Umana G, Dzierba J, Weintraub D. Antibody response in serum and nasopharynx after naturally acquired and vaccine induced infection with rubella virus. *N Engl J Med* 1971; 285:1333-9.
38. Plotkin SA, Farquhar JD, Ogra PL. Immunologic properties of RA 27/3 rubella virus vaccine. *JAMA* 1973; 225:585-90.
39. Liebhaber H, Ingalls TH, LeBouvier GL, Horstmann DM. Vaccination with RA 27/3 rubella vaccine. Persistence of immunity and resistance to challenge after two years. *Am J Dis Child* 1972; 123:133-6.
40. Farquhar JD. Follow-up on rubella vaccinations and experience with subclinical reinfection. *J Pediatr* 1972; 81:460-5.
41. National Advisory Committee on Immunization (NACI). Anaphylactic Hypersensitivity to Egg and Egg-Related Antigens, in: *Canadian Immunization Guide, Seventh Edition, 2006*, p. 85-86.

**PART III: CONSUMER INFORMATION****M-M-R® II**

(measles, mumps and rubella virus vaccine, live, attenuated, Merck Std.)

This leaflet is part III of a three-part "Product Monograph" and is designed specifically for Consumers. This leaflet is a summary and will not tell you everything about M-M-R® II. Contact your doctor or pharmacist if you have any questions about the vaccine.

**ABOUT THIS VACCINE**What the vaccine is used for:

M-M-R® II is an injectable live virus vaccine to help prevent measles (rubeola), mumps, and rubella (German Measles).

Why has my doctor prescribed M-M-R® II?

Your doctor has recommended or administered M-M-R® II to help protect you or your child against measles, mumps, and rubella. The vaccine can be administered to persons 12 months of age or older.

**Measles** is a serious disease that is very easily passed from one person to another. It causes a high fever, cough, and a rash and lasts for 1 to 2 weeks. One out of every 10 children who catch measles will also have an ear infection or pneumonia. On rare occasions, measles can also cause an infection of the brain that could lead to seizures, hearing loss, mental retardation, and even death. Babies and adults who catch measles are often much sicker for a longer time or are more likely to die than elementary school children and teenagers who catch measles.

**Mumps** is easily passed from one person to another and causes fever, headache, and swollen, painful glands under the jaw (salivary glands). It can sometimes be a very serious disease and usually lasts for several days. Mumps can cause a mild inflammation of the coverings of the brain and spinal cord (meningitis) in about 1 person in every 10 who catch it. About 1 out of every 4 teenage or adult males with mumps will have a painful swelling of the testicles for several days (this does not usually affect their ability to father children). Teenagers and adults, especially males, who catch mumps are often much sicker and more likely to suffer longer than children do.

**Rubella** is usually a mild disease that causes a mild fever, swollen glands in the neck, pain and swelling in the joints, and a rash that lasts for a short time **but is very dangerous if a pregnant woman catches it**. Women who catch rubella when they are pregnant can have babies who are stillborn, or have heart disease, blindness, deafness, or problems with learning.

What the medicinal ingredient is:

measles, mumps and rubella virus vaccine, live

What the important non-medicinal ingredients are:

M-M-R® II contains neomycin, gelatin and recombinant human albumin as inactive ingredients. Tell your doctor if you

or your child has ever had an allergic reaction to these ingredients.

*For a full listing of non-medicinal ingredients see Part I of the product monograph.*

What dosage forms it comes in:

M-M-R® II is supplied as follows:

- a box of 10 single-dose vials of lyophilized vaccine, and
- a box of 10 vials (0.7 mL) of diluent.

**WARNINGS AND PRECAUTIONS**What should I tell my doctor before vaccination with M-M-R® II?

Tell your doctor about any medical problems you or your child has or has had, and about any allergies (especially to neomycin).

Tell your doctor if you or your child has a history of convulsions or a brain injury, or a low blood platelet count.

Who should not be vaccinated with M-M-R® II?

Anyone who:

- is allergic to any of its components (including neomycin)
- is pregnant (in addition, pregnancy should be avoided for 3 months after vaccination)
- has a fever
- has active untreated tuberculosis
- is taking medications to suppress their immune system (other than corticosteroid replacement)
- has a blood disorder or any type of cancer that affects their immune system
- has an immune deficiency as a result of a disease or a treatment

Use in children

M-M-R® II should be used in children 12 months of age or older. However, your doctor may recommend that M-M-R® II be given to infants who are less than 12 months of age in special situations.

Use in pregnancy

M-M-R® II should not be administered to pregnant women. Women of child-bearing age should take the necessary precautions to avoid pregnancy for 3 months following vaccination.

Use in breast-feeding

Tell your doctor if you are breast-feeding or intend to breast-feed. Your doctor will decide if you should receive M-M-R® II.

**INTERACTIONS WITH THIS VACCINE**

Administration of immunoglobulins with M-M-R® II may

interfere with immune response.

Tell your doctor if your child has received blood or plasma transfusions or administration of human serum globulin within the last 3 months.

### PROPER USE OF THIS VACCINE

#### Usual Dose:

M-M-R<sup>®</sup> II is given by injection as follows:

- M-M-R<sup>®</sup> II is given to persons 12 months of age or older. The dose of the vaccine is the same for everyone.
- For persons vaccinated at 12 months of age or older, a second dose of the vaccine is recommended at a later date which will be decided by your doctor.
- Children first vaccinated at less than 12 months of age should receive two additional doses after reaching 12 months of age.
- Non-pregnant adolescent and adult females of childbearing age who are susceptible to rubella can be vaccinated with M-M-R<sup>®</sup> II (or live attenuated rubella virus vaccine) if certain precautions are observed (see Use in Pregnancy). It has been found convenient in many instances to vaccinate women who are susceptible to rubella in the immediate post-partum period.

See your doctor for more details.

#### Overdose:

In case of overdose, contact a health care practitioner, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

#### Missed dose

Your doctor will decide when to give the missed dose.

### SIDE EFFECTS AND WHAT TO DO ABOUT THEM

#### What undesirable effects may M-M-R<sup>®</sup> II have?

Any vaccine may have unintended or undesirable effects, so-called side effects. The most common is burning and/or stinging at the injection site for a short time. Transient joint pain and/or swelling have occurred more frequently in adult females; sometimes these symptoms may be chronic. Occasionally, fever and rash may occur. Rarely, unusual bleeding or bruising under the skin, and swelling of the testicles may occur.

Other side effects may also occur rarely and some of these may be serious. These include allergic reactions, seizures, and inflammation of the nervous system (brain and/or spinal cord). Your doctor has a more complete list of side effects.

Tell your doctor promptly about any of these or any other unusual symptoms. If the condition persists or worsens, seek

medical attention.

### HOW TO STORE IT

Vial of powder: Store at 2°C to 8°C. The vaccine may also be stored in a freezer at temperatures above -50°C; if subsequently transferred to a refrigerator, the vaccine may be placed back in the freezer. Keep the vial in the outer carton in order to protect from light.

Diluent: Store separately from the vaccine vial at room temperature (20°C to 25°C) or in the refrigerator at 2°C to 8°C.

#### Reporting Suspected Vaccine Adverse Events

##### **For the general public:**

If you suspect you have had a serious or unexpected event following receipt of a vaccine, please ask your healthcare professional to complete the Adverse Events Following Immunization (AEFI) Form and send it to your local [health unit](#) in your province/territory.

##### **For healthcare professionals:**

If a patient experiences an adverse event following immunization, please complete the Adverse Events Following Immunization (AEFI) Form and send it to your local [health unit](#) in your province/territory.

If you have any questions or have difficulty contacting your local health unit, please contact Vaccine Safety Section at Public Health Agency of Canada:

Toll-free telephone: 1-866-844-0018

Toll-free fax: 1-866-844-5931

By email: [caefi@phac-aspc.gc.ca](mailto:caefi@phac-aspc.gc.ca)

*NOTE: Should you require information related to the management of the adverse events, please contact your health professional before notifying the Public Health Agency of Canada. The Public Health Agency of Canada does not provide medical advice.*

**MORE INFORMATION**

**If you want more information about MMR<sup>®</sup> II:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Consumer Information by visiting the Health Canada website or Merck Canada website [www.merck.ca](http://www.merck.ca) or by calling Merck Canada at 1-800-567-2594

To report an adverse event related to MMR<sup>®</sup> II, please contact 1-800-567-2594.

This leaflet was prepared by Merck Canada Inc.

Last revised: November 28, 2016

<sup>®</sup> Merck Sharp & Dohme Corp. Used under license.

© 2011, 2016 Merck Canada Inc. All rights reserved.